What is Moderna's market cap?

Moderna (MRNA) has a market capitalization of $29.3B and trades on NASDAQ.

What is Moderna's revenue and profitability?

Moderna generated $2.2B in trailing twelve-month revenue with a net loss of $3.2B, representing a net margin of -143.6%. Gross margin stands at 22.1%, with free cash flow of -$3.6B. These figures are based on the Q1 2026 filing.

Who are Moderna's competitors?

Moderna's key competitors include Pfizer, BioNTech, Sanofi, and others. These companies compete in similar markets and product categories.

Who does Moderna partner with?

Moderna's notable partners include Merck & Co., Recordati, Pfizer, and others.

Where is Moderna headquartered?

Moderna is headquartered in United States of America and employs approximately 5,600 people. It has been publicly traded since 2018.

Moderna

MRNA

Moderna is a biotechnology company that pioneered a proprietary messenger RNA (mRNA) platform to develop a new class of medicines.

Market cap

$29.28B+148%

Revenue$2.2B-30.0%

Net income-$3.2B+4.9%

Free cash flow-$3.6B+16.3%

EPS (diluted)-$8.15+6.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 1, 2026

Revenue$389.0MBeat by $152.6M EPS-$1.18Beat by $1.84

Read the full report

Next report

Jul 31, 2026 (In 3 weeks)

Revenue estimate$101.7M

EPS estimate-$2.00

Financials

Q1 2026

Income statement

See full

Revenue$389.0M+260%

Gross profit-$566.0M-3,244%

Operating income-$1.4B-32.2%

Net income-$1.3B-38.3%

EPS (diluted)-$3.40-34.9%

Balance sheet

See full

Cash & equivalents$1.9B+17.4%

Total debt$1.3B+71.9%

Total equity$7.4B-26.4%

Total assets$11.5B-9.6%

Cash flow

See full

Operating cash flow-$630.0M+39.2%

CapEx$62.0M-47.0%

Free cash flow-$692.0M+40.0%

Valuation & ratios

Valuation

See full

Market cap$29.28B+148%

Enterprise value$28.7B+154%

P/S13.2×+9.3×

Profitability

See full

Gross margin22.1%-32.0pp

Operating margin-153.3%+67.8pp

Net margin-143.6%+80.2pp

Returns & leverage

See full

Return on equity-36.6%+11.9pp

Debt / equity0.2×+0.1×

Current ratio2.4×-1.8×

Segments

By product

See full

Stand-ready manufacturing revenue$32.0M+167%

Collaboration Arrangement, Including Arrangements With Affiliate$5.0M+400%

Grant revenue--100%

Licensing and royalty revenue--100%

Competitors

By market cap

Merck & Co.$311.17B+53.1%

Pfizer$137.07B-5.0%

Moderna$29.3B+148%

Viridian Therapeutics, Inc.$2.2B+71.5%

Novavax$1.5B+39.6%

Invivyd, Inc.$244.5M+177%

Arcturus Therapeutics$207.5M-44.5%

GeoVax Labs$6.0M-20.9%

By revenue growth

Viridian Therapeutics, Inc.+23,383%

Merck & Co.+2.9%

Pfizer+1.4%

Moderna-30.0%

Novavax-52.5%

By net margin

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

Novavax-14.73%-52.9pp

Moderna-143.55%-37.9pp

Viridian Therapeutics, Inc.-508.46%+101,584pp

Profile

Moderna is a biotechnology company that pioneered a proprietary messenger RNA (mRNA) platform to develop a new class of medicines. The company's technology functions as 'software' for life, instructing cellular machinery to produce specific proteins to prevent or treat infectious diseases, immuno-oncology, and rare genetic disorders. Their primary value proposition lies in a rapid, scalable manufacturing network and a versatile platform that can address multiple therapeutic areas using the same underlying science.

Competitive position

Moderna is a dominant leader in the mRNA space with a first-mover advantage in mRNA vaccines and a highly integrated global manufacturing footprint.

GeographiesUnited States, United Kingdom, Canada, Australia, Europe

Customer segmentsGovernments, Retail pharmacies, Healthcare systems

Business modelR&D intensive, Product manufacturing and sales, Strategic licensing and collaborations

SuppliersNucleotide suppliers, Lipid nanoparticle raw materials, Specialized laboratory equipment, Contract research organizations

CustomersPublic health departments, Wholesale pharmaceutical distributors, Retail pharmacy chains, Hospitals

CountryUnited States of America

Listed2018

Employees5.6K

CEOStéphane Bancel

SectorHealthcare

IndustryBiotechnology

Websitemodernatx.com

FilingsSEC EDGAR

Ask your AI about Moderna.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Moderna's market cap?: Moderna (MRNA) has a market capitalization of $29.3B and trades on NASDAQ.
What is Moderna's revenue and profitability?: Moderna generated $2.2B in trailing twelve-month revenue with a net loss of $3.2B, representing a net margin of -143.6%. Gross margin stands at 22.1%, with free cash flow of -$3.6B. These figures are based on the Q1 2026 filing.
Who are Moderna's competitors?: Moderna's key competitors include Pfizer, BioNTech, Sanofi, and others. These companies compete in similar markets and product categories.
Who does Moderna partner with?: Moderna's notable partners include Merck & Co., Recordati, Pfizer, and others.
Where is Moderna headquartered?: Moderna is headquartered in United States of America and employs approximately 5,600 people. It has been publicly traded since 2018.